PARP inibitors and ONX-0801 in ovarian cancer

Stan Kaye, BSc, MD, FRCP, FRCR, FRSE, FMedSci of Royal Marsden NHS Foundation Trust, London, UK discusses improvements in ovarian cancer care. Treatments need to improve as the disease is usually fatal with an average survival of 5-6 years. A significant number of women with ovarian cancer have an inherited disease related to BRCA1 or BRCA2 gene, which render the disease susceptible to PARP inhibitor treatment. Prof Kaye mentions a folate receptor alpha (FRα), which is highly expressed in ovarian cancer. Studies targeting FRα using ONX-0801 drug candidate are ongoing. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
Share this video